Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections

References

• Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J. Am. Acad. Dermatol.50(3), 331–340 (2004).
   PubMed Web of Science ®Google Scholar
• Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy26(7), 908–918 (2006).
   PubMed Web of Science ®Google Scholar
• Lin G, Smith K, Ednie LM, Appelbaum PC. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob. Agents Chemother.49(12), 5182–5184 (2005).
   PubMed Web of Science ®Google Scholar
• Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis.54(2), 149–153 (2006).
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert. Rev. Anti Infect. Ther.4(4), 601–618 (2006).
   PubMedGoogle Scholar
• Ellis MW, Lewis JS 2nd. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis.18(6), 496–501 (2005).
   PubMed Web of Science ®Google Scholar
• Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother.55(Suppl. 2), ii25–ii30 (2005).
   PubMed Web of Science ®Google Scholar
• Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect.50(3), 206–209 (2005).
   PubMed Web of Science ®Google Scholar
• Barrett JF. Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs6(8), 781–790 (2005).
   PubMedGoogle Scholar
• Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs12(3), 379–399 (2003).
   PubMed Web of Science ®Google Scholar
• Leadbetter MR, Adams SM, Bazzini B et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo)57(5), 326–336 (2004).
   PubMed Web of Science ®Google Scholar
• Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet.11(4), 257–282 (1986).
   PubMed Web of Science ®Google Scholar
• Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert. Rev. Anti Infect. Ther.4(5), 743–749 (2006).
   PubMedGoogle Scholar
• Stryjewski ME, O’Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis.40(11), 1601–1607 (2005).
   PubMed Web of Science ®Google Scholar
• Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int. J. Clin. Pract.61(5), 853–863 (2007).
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis.41(10), 1407–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus Antimicrob. Agents Chemother.49(8), 3163–3165 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother.49(1), 195–201 (2005).
   PubMed Web of Science ®Google Scholar
• Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother.50(2), 788–790 (2006).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol.4(5), 471–478 (2004).
   PubMed Web of Science ®Google Scholar
• Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin. Investig. Drugs16(5), 717–733 (2007).
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother.55(Suppl. 2), ii15–ii20 (2005).
   PubMed Web of Science ®Google Scholar
• Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin. Investig. Drugs16(3), 347–357 (2007).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs7(8), 740–749 (2006).
   PubMed Web of Science ®Google Scholar
• Padmanabhan RA, Larosa SP, Tomecki KJ. What’s new in antibiotics? Dermatol. Clin.23(2), 301–312 (2005).
   Google Scholar
• Lin SW, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of Gram-positive infections. Ann. Pharmacother.40(3), 449–460 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson DM, Fritsche TR, Sader HS, Jones RN. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int. J. Antimicrob. Agents27(6), 557–560 (2006).
   PubMed Web of Science ®Google Scholar
• Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy25(10 Pt 2), 55–62S (2005).
   PubMed Web of Science ®Google Scholar
• Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.58(6), 1177–1184 (2006).
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.49(3), 1127–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs64(9), 913–936 (2004).
   PubMed Web of Science ®Google Scholar
• Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol.71(7), 968–980 (2006).
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN. Activity of dalbavancin tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol.45(3), 998–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis.48(2), 137–143 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. (Larchmt)6(3), 283–295 (2005).
   PubMedGoogle Scholar
• Krause K, Benton B, Higgins D et al. Telavancin (TLV) possesses low potential for resistant mutant selection in serial poassage studies of Staphylococcus aureus and enterococci. Presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark 2–5 April (2005).
   Google Scholar
• King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother.53(5), 797–803 (2004).
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J. Antimicrob. Chemother.60(3), 681–684 (2007).
   PubMed Web of Science ®Google Scholar
• Torres-Viera C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr. Opin. Infect. Dis.17(6), 541–547 (2004).
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother.51(5), 1633–1642 (2007).
   PubMed Web of Science ®Google Scholar
• Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin. Investig. Drugs16(2), 137–155 (2007).
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.60(2), 406–409 (2007).
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother.48(8), 3043–3050 (2004).
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect.11(2), 95–100 (2005).
   PubMed Web of Science ®Google Scholar
• Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol.8(5), 510–517 (2005).
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother.48(3), 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Hoffman-Roberts HL, C Babcock E, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin. Investig. Drugs14(8), 973–995 (2005).
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Riva S, Valagussa A et al. Pharmacokinetics and excretion of dalbavancin in the rat. J. Antimicrob. Chemother.55(Suppl. 2), ii31–ii35 (2005).
   PubMed Web of Science ®Google Scholar
• Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J. Antimicrob. Chemother.58(3), 627–631 (2006).
   PubMed Web of Science ®Google Scholar
• Telavancin: TD 6424, TD-6424. Drugs R. D.7(6), 384–388 (2006).
   Google Scholar
• Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.49(10), 4344–4346 (2005).
   PubMed Web of Science ®Google Scholar
• Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr. Infect. Dis. Rep.3(1), 29–34 (2001).
   PubMedGoogle Scholar
• Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother.56(2), 337–343 (2005).
   PubMed Web of Science ®Google Scholar
• Sahm D, Benton B, Jones M et al. Interaction of telavancin and other antimicrobial agents tested against key Gram-positive species. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA, 27–30 Spetember (2006).
   Google Scholar
• Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis.37(10), 1298–1303 (2003).
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis.40(3), 374–380 (2005).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother.50(3), 862–867 (2006).
   PubMed Web of Science ®Google Scholar
• Corey R, Stryjewski M, W OR et al. Telavancin for the treatment of complicated skin and skin structure infections (cSSSI): results of the ATLAS I study. Presented at: 44th Infectious Disease Society of America Toronto, Canada, October (2006)
   Google Scholar
• Campbell KC, Kelly E, Targovnik N et al. Audiologic monitoring for potential ototoxicity in a Phase I clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol.14(3), 157–168 (2003).
   PubMedGoogle Scholar
• Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol.44(7), 689–695 (2004).
   PubMed Web of Science ®Google Scholar
• Pace JL, Judice JK. Telavancin (Theravance). Curr. Opin. Investig. Drugs6(2), 216–225 (2005).
   PubMedGoogle Scholar
• DeCorby M, Laing N, Weshoweski B et al. Activity of dalbavancin against S. aureus, MRSA, S. epidermidis and VRE isolated from Canadian intensive care units: results of the CAN-ICU study. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA 17–20 Spetember (2007).
   Google Scholar
• Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs64(15), 1621–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Guay DR. Dalbavancin: an investigational glycopeptide. Expert. Rev. Anti Infect. Ther.2(6), 845–852 (2004).
   PubMedGoogle Scholar